Research and Markets: The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d14516/the_gastrointestin) has announced the addition of the "The Gastrointestinal Market Outlook To 2014: Market Dynamics, Competitive Landscape, Emerging Therapies" report to their offering.

Gastrointestinal disorders are quite diverse affecting different parts of the alimentary tract such as the pancreas, oropharynx, liver and biliary system and the alimentary canal. Causes of these disorders vary and could include genetic anomalies, the effect of certain toxins and drugs, infections, cancer and often unknown causes. Disorders of the gastrointestinal tract (GIT) are fairly common and occur in people of all ages. These disorders take up a significant share of the disease burden in developed economies and the gravity of the problem is further accentuated by the difficulty that they pose in effective management. GIT therapy area consists of some indications that can be treated through pharmacologic interventions, though significant unmet need still exists. These unmet medical needs are more common for indications such as irritable bowel syndrome (IBS), Crohn's disease (CD) and ulcerative colitis (UC).

An incomplete understanding of the etiologies of these diseases limits their effective treatment, leading to misguided treatment and misdiagnosis. A significant fraction of the drugs used in the GIT therapy area are for the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). The therapy area overall, however, reflects significant levels of genericization with R&D efforts drifting towards novel therapies for Crohn's disease and inflammatory bowel disease (IBD). In several instances though, the shift could be out of GIT to the faster growing therapy areas such as oncology, cardiovascular disorders and autoimmune disorders.

The gastrointestinal market was valued at $49.9bn in 2008 and US took the largest share of this market (37.8%) with sales amounting to $18.8bn. The gastrointestinal market reflects a high degree of genericization and is quite mature. The other three categories of brands ($23.7bn) captured almost as much in sales as original and licensed brands together ($26.3bn), a trend much in contrast to the high-growth therapy areas such as diabetes and oncology, where genericization is less prevalent.

The growth of the GI therapeutic area has so far hinged on the performance of the PPI drug class. The interplay of brands within this drug class has shaped the market dynamics. Over the forecast period, the GI market's growth will be determined by the growth of the immunosuppressants and antirheumatic agents. These two drug classes are led by biologics such as Remicade and Humira, which are less prone to genericization and with the appearance of newer agents such as Cimzia, the market is expected to expand further. This report provides an overview of key events in the global gastrointestinal market that have impacted treatment trends and sales potential.

Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios can be obtained using this report.

Scope of this report

• Epidemiological analysis of the therapy area and forecast prevalence over the period 2009-14
• Forecasts and analysis of the key products in the gastrointestinal market over the period 2009-14 across major classes of treatments
• Detailed analysis across major classes of gastrointestinal treatment including immunosuppressants and anti-rheumatic agents
• Detailed analysis of the clinically differentiated products in the gastrointestinal market pipeline and sales forecast of key R&D pipeline products in the global gastrointestinal market

Key findings from this report

• Growth in the Crohn's disease and ulcerative colitis market is likely to be driven by self-injectable products. This would lead to the transition of a significant proportion of patients on Remicade therapy to these products. The convenience of self-injection would help in driving growth in this category while facilitating earlier use of drugs. These dynamics have the potential to fuel growth while expanding the market in these categories.
• AstraZeneca has constituted a new company, which will be funded by three private equity firms, with several of its gastrointestinal programs. This new biotech venture of the company, called Albireo, has taken up one early stage clinical program, besides some preclinical programs of the company. The private equity firms involved are - TVM Capital, Phase4 Ventures and Scottish Widows Investment Partnership. This new venture of AstraZeneca is a bid towards streamlining its gastrointestinal development projects in key indications such as GERD and for line extensions of its market leading product Nexium.
• Many of the top ten players posted a decline in sales over 2007, a fact indicative of the high degree of genericization in the market. Over all, drugs indicated for the treatment of ulcer are expected to drag down the sales of most players. Thus, companies that have maintained a more diverse drug class portfolio are expected to gain more in the long run.

Key Topics Covered:

• Executive summary
• Chapter 1 Patient potential
• Chapter 2 Gastrointestinal market dynamics
• Chapter 3 Key investigational compounds
• Chapter 4 Leading players of the gastrointestinal market
• Chapter 5 Appendix
• List of Figures
• List of Tables

Companies Mentioned:

• AstraZeneca
• Eisai
• J&J
• Nycomed
• Takeda
• Takeda
• Wyeth

For more information visit http://www.researchandmarkets.com/research/d14516/the_gastrointestin

Source: Business Insights